Metoprolol

References 1. Rubinstein A, "Approaches and opportunities in colon specific drug delivery", Drug Carrier Syst 1995 12: pp. 101149. 2. Tozer T R, Friend D R, McLeod A D, "Kinetic perspectives on colonic delivery", S T P Pharma Sci 1995 5: pp. 528. 3. Godbillon J, Evard D, Vidon N et al., "Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon", Br J Clin Pharmacol 1985 19: pp. 113S118S. 4. Antonin K H Bieck P, Scheurlen M, Jedrychowski M, Malchow H, "Oxprenolol absorption in man after single bolus dosing in two segments of the colon compared with that after oral dosing", Br J Clin Pharmacol 1985 19: pp. 137S142S. 5. Rubinstein A, "Approaches and opportunities in colon specific drug delivery", Drug Carrier Syst 1995 12: pp. 101-149. 6. Conchie J, Macleod D C, "Glycosidase in mammalian alimentary tract", Nature 1959 184: p. 1, 233. 7. Kinget R, Kalala W, Vervoort L, Mooter G, "Colonic drug targetting", J Drug Target 1998 6: pp. 129149. 8. Watts P J, Illum L, "Colonic drug delivery", Drug Dev Ind Pharm 1997 23: pp. 893913. 9. Yang L, Chu J S, Fix J A, "Colon specific drug delivery: new approaches and in vitro in vivo evaluation", Int J Pharm 2002 235: pp. 115. 10. Kinget R, Kalala W, Vervoort L, Mooter G, "Colonic drug targetting", J Drug Target 1998 6: pp. 129149. 11. Basit A W, Lacey L F, "Colonic metabolism of renitidine: implications for its delivery and absorption", Int J Pharm 2001 227: pp. 157165. 12. Rubinstein A, "Approaches and opportunities in colon specific drug delivery", Drug Carrier Syst 1995 12: pp. 101149. 13. Friend D, Chang G W, "A colon-specific drug delivery based on the drug glycosidases of colonic bacteria", J Med Chem 1984 27: pp. 261266. 14. Nakamura J, Asai K, Nishida K, Sasaki H, "A novel prodrug of salicylic acid, salicylic acidglutamic acid conjugate utilizing hydrolysis in rabbit intestinal microorganisms", Chem Pharm Bull 1992 40: pp. 2, 1642, 168. Mooter G V D, Maris B, Samyn C, Augustijns P, Kinget R, "Use of axo polymers for colon specific drug delivery", J Pharm Sci 1997 86: pp. 1, 3211, 327. Kopecek J, Kopeckova P, N- 2-hydroxypropyl ; methacrylamide Copolymers for Colon Specific Drug Delivery, 1992 ; London: CRC Press; p. 189. 17. Klotz U, "Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid", Clin Pharmacokinetic 1985 10: pp. 285302. 18. Szejtli J, "Medical applications of cyclodextrins", Med Res Rev 1994 14: pp. 353386. 19. Loftsson T, Brewster M E, "Pharmaceutical applications of cyclodextrins 1: drug solubilization and stabilization", J Pharm Sci 1996 85: pp. 1, 0171, 025. Flourie B, Molis C, Achour L et al., "Fate of , -Cyclodextrins in the Human Intestine", J. Nutr. 1993 ; , 123: pp. 676680. 21. Hehre E J, Sery T W, "Dextran-splitting anaerobic bacteria from the human intestine", J Bacteriol 1956 71: pp. 373380. 22. Dew M J, Hughes P J, Lee M G, Evans B K, Rhodes J, "An oral preparation to release drugs in the human colon", Br J Clin Pharmacol 1982 14: pp. 405408. 23. Tuleu C, Andrieux C, Cherbuy C et al., "Colonic delivery of sodium butyrate via oral route: acrylic coating design of pellets and in vivo evaluation in rats", Methods Find Exp Clin Pharmacol 2001 23: pp. 245253. 24. Ibekwe V C, Fadda H M, Parsons G E, Basit A W, "A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery", Int J Pharma 2006 308: pp. 5260. 25. Spitael J, Kinget R, Naessens K, "Dissolution rate of cellulose acetate phthalate and bronsted catalysis", Pharm Ind 1980 42: pp. 846849. 26. Devereux J E, Newton J M, Short M B, "The influence of density on the gastrointestinal transit of pellets", J Pharm Pharmacol 1990 42: pp. 500501. 27. Davis S S, Hardy G G, Fara J W, "Transit of pharmaceutical dosage forms through the small intestine", Gut 1986 27: pp. 886892. 28. Theeuwes F, Yum S I, Haak R, Wong P, "Systems for triggered, pulsed and programmed drug delivery", Temp Cont Drug Del 1991 pp. 428440. 29. Chako A, Szaz K F, Howard J, Coummings J H, "Non-invasive method for delivery of tracer substances or small quantities of other materials to the colon", Gut 1990 31: pp. 106110. 30. Rashid A, Dispensing Device 1990 Eur Patent Application: 0384642. 31. Pozzi F, Furlani P, Gazzaniga A, Davis S S, Wilding I R, "The time clock system: a new oral dosage form for fast and complex release of drug after a predetermined lag time", J Control Release 1994 31: pp. 99-104. 32. Kellow J E, Borody T J, Phillips S F, "Human interdigestive motility: variations in patterns from oesophagus to colon", Gastroenterol 1986 91: pp. 386395. 5 and oxycodone and metoprolol.

Other states like kentucky, west virginia are experiencing prescription drug abuse, but nowhere has been hit harder than maine, says sen. All services a-z drug list drugs & medications diseases & conditions news & articles pill identifier interactions checker drug side effects drug image search new drug approvals new drug applications fda drug alerts clinical trial results patient care notes medical encyclopedia medical dictionary medical videos - community forums for professionals drug imprint codes medical abbreviations veterinary drugs contact us news feeds advertise here recent searches percocet spironolactone xolair herceptin fosrenol myozyme ultracet cardizem levothyroxine ellence alli viagra propecia xenical botox levitra lupron roxicet veramyst synthroid bisoprolol risperdal metorolol invega revatio recently approved totect acam2000 somatuline depot evithrom zingo selzentry evamist calomist privigen atralin gel more and oxycontin.
Clinical trials merit-hf was a double-blind, placebo-controlled study of mehoprolol succinate extended- release tablet conducted in 14 countries including the usa it randomized 3991 patients 1990 to metoprolol succinate extended-release tablets ; with ejection fraction 40 and nyha class ii-iv heart failure attributable to ischemia , hypertension, or cardiomyopathy.
Maack c, et al : different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Generally, medicines should be used at the lowest effective dose. 4. Wikstrand J, Warnold I, Olsson G et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. J Med Assoc 1988; 259: 19761982. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503510. Herlitz J, Waagstein F, Lindqvist J et al. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure a subgroup analysis of the Gteborg Metoprolol Trial ; . J Cardiol 1997; 80: 40J44J. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 10221036. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980; 44: 117133. Gibelin P, Sbirrazzuoli V, Drici M et al. Role of myocardial beta-adrenergic receptors in cardiac insufficiency. Ann Cardiol Angeiol 1990; 39: 165171. Waagstein F, Caidahl K, Wallentin I et al. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551563. Halawa B. Trends in pharmacological treatment of congestive heart failure. Pol Merkuriusz Lek 1999; 6: 152156. Andersson B, Blomstrom-Lundqvist C, Hedner T, Waagstein F. Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure. J Coll Cardiol 1991; 18: 10591066. Kukin ML, Kalman J, Charney RH et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 26452651. Andersson B, Caidahl K, di Lenarda A et al. Changes in early and late diastolic filling patterns induced by long- term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 673682. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980; 44: 134142. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy MDC ; Trial Study Group. Lancet 1993; 342: 14411446.
Personally, i a fan of the esmolol small boluses, and then when shown effective, titrate in some metoprolol and miacalcin.
Table traditional cardiovascular risk factors smoking possibly including passive smoke exposure ; diabetes hypertension dyslipidemia well defined: high total and low-density lipoprotein cholesterol levels, high triglyceride levels, low high-density lipoprotein cholesterol level ; age more than 50 yr male sex postmenopausal state obesity especially with syndrome x or hyperinsulinism ; several studies have pointed to cigarette smoking as the most prominent high-risk behavior in pathogenesis of peripheral arterial disease.

JAMES M. BRUNDEGE AND JOHN T. WILLIAMS The Vollum Institute, Oregon Health Sciences University, Portland, Oregon 97201. Study Sanerson et al.82 -blockade in heart failure: comparison between carvedilol and metoprolol.
An 83-year-old woman presented with a 2-day history of difficulty walking. She had a background of ischaemic heart disease, chronic renal failure, hypertension, peptic-ulcer disease and gout. Nicorandil and candesartan had been withdrawn 2 weeks previously due to acute chronic renal impairment serum creatinine rise from 230 to 332 mmol L ; . A serum CK performed 2 weeks previously was 70 U L. Medications on admission were pantoprazole, allopurinol, clopidogrel, metoprolol and frusemide. She had also been taking simvastatin 40 mg day for 5 years. She demonstrated grade 4 5 upper limb and 3 5 lowerlimb proximal-muscle weakness. Urine was positive for myoglobin. Simvastatin was ceased. Initial CK was 3200 U L and peaked at 11 300 U L 6 days later. Electromyography showed small, brief duration and polyphasic motor units consistent with a myopathy. A muscle biopsy revealed muscle necrosis and four of 20 muscle fibres seen in the biopsy specimen contained rimmed vacuoles under light microscopy Fig. 1 ; . Electron microscopy confirmed the presence of tubulo-filamentous inclusion bodies Fig. 2 ; . Oral prednisolone 30 mg day was commenced. She was able to mobilize short distances with a frame 14 days after admission, at which time her CK had normalized and her serum creatinine improved to 235 mmol L. Corticosteriod therapy was withdrawn on discharge. However, proximal muscle weakness persisted and she was still unable to weight-bear without assistance on last review, 6 months postdischarge. Tachycardia occurs in up to 10% of patients with advanced heart failure who are referred for cardiac transplantation. In patients with ischaemic heart disease these arrhythmias often have re-entrant mechanisms in scarred myocardial tissue. An episode of sustained ventricular tachycardia indicates a high risk for recurrent ventricular arrhythmias and sudden cardiac death. Sustained polymorphic ventricular tachycardia and torsades de pointes are more likely to occur in the presence of precipitating or aggravating factors, including electrolyte disturbance for example, hypokalaemia or hyperkalaemia, hypomagnesaemia ; , prolonged QT interval, digoxin toxicity, drugs causing electrical instability for example, antiarrhythmic drugs, antidepressants ; , and continued or recurrent myocardial ischaemia. Blockers are useful for treating arrhythmias, and these agents for example, bisoprolol, metoprolol, carvedilol ; are likely to be increasingly used as a treatment option in patients with heart failure. Stroke and thromboembolism Congestive heart failure predisposes to stroke and thromboembolism, with an overall estimated annual incidence of approximately 2%. Factors contributing to the increased thromboembolic risk in patients with heart failure include low cardiac output with relative stasis of blood in dilated cardiac chambers ; , regional wall motion abnormalities including formation of a left ventricular aneurysm ; , and associated atrial fibrillation. Although the prevalence of atrial fibrillation in some of the earlier observational studies was between 12% and 36%--which may have accounted for some of the thromboembolic events--patients with chronic heart failure who remain in sinus rhythm are also at an increased risk of stroke and venous thromboembolism. Patients with heart failure and chronic venous insufficiency may also be immobile, and this contributes to their increased risk of thrombosis, including deep venous thrombosis and pulmonary embolism. Recent observational data from the studies of left ventricular dysfunction SOLVD ; and vasodilator heart failure trials V-HeFT ; indicate that mild to moderate heart failure is associated with an annual risk of stroke of about 1.5% compared with a risk of less than 0.5% in those without heart failure ; , rising to 4% in patients with severe heart failure. In addition, the survival and ventricular enlargement SAVE ; study recently reported an inverse relation between risk of stroke and left ventricular ejection fraction, with an 18% increase in risk for every 5% reduction in left ventricular ejection fraction; this clearly relates thromboembolism to severe cardiac impairment and the severity of heart failure. As thromboembolic risk seems to be related to left atrial and left ventricular dilatation, echocardiography may have some role in the risk stratification of thromboembolism in patients with chronic heart failure. This group of adrenoceptor ligands also known as -adrenergic receptor blocking drugs, -adrenoceptor blocking drugs, or beta-blockers are drugs that inhibit certain actions of the sympathetic nervous system by preventing the action of adrenaline and noradrenaline catecholamine mediators acting predominantly as hormone or neurotransmitter, respectively ; by acting as antagonists at the -adrenoceptors through which they act. Correspondingly, -ADRENOCEPTOR ANTAGONISTS are drugs used to inhibit the remaining actions by occupying the other class of adrenoceptor, -adrenoceptors. ; Among other actions, -adrenoceptors have cardiac stimulant actions, they dilate certain blood vessels, suppress motility within the gastrointestinal tract, stimulate certain aspects of metabolism causing an increase in glucose and free fatty acids in the blood. These actions, in concert with those of the -adrenoceptors, help prepare the body for emergency action. However, in disease, some of these actions may be inappropriate, exaggerated, and detrimental to health, so -blockers may be used to restore the balance. Thus -blockers are used to lower blood pressure when it is abnormally raised in cardiovascular disease see ANTIHYPERTENSIVE AGENTS ; , to correct certain heartbeat irregularities and tachycardias see ANTIARRHYTHMIC AGENTS ; , to prevent the pain of angina pectoris during exercise by limiting cardiac stimulation see ANTIANGINAL AGENTS ; , to treat myocardial infarction associated with heart attacks ; , as prophylaxis to reduce the incidence of migraine attacks see ANTIMIGRAINE AGENTS to reduce anxiety, particularly its manifestations such as muscular tremor see ANTIANXIETY AGENTS as short-term treatment prior to surgical correction of thyrotoxicosis see ANTITHYROID AGENTS and as eye-drops to lower raised intraocular pressure in glaucoma treatment. However, there is commonly a price to pay for extensive alteration in autonomic processes in the body. For instance adverse effects include precipitation of asthma attacks so asthma sufferers will require bigger doses of -receptor stimulant aerosols for their complaint ; . Similarly, the blood-flow in the extremities will often be reduced, so patients may well complain of cold feet or hands. It may be possible to gain some selectivity of drug action, with consequent minimisation of side-effects, by using receptor-subtype-selective -blockers. Thus, 1-adrenoceptor antagonists have a higher affinity for the 1-adrenoceptor of the heart, and thus they may have some preferential action there, since 2-adrenoceptors are found at most other sites in the body including the airways and blood vessels. Antagonists with similar affinity for 1-adrenoceptor and 2-adrenoceptors include: propranolol, nadolol, oxprenolol and timolol; whereas metoprolol, atenolol, esmolol and acebutolol show some 1-adrenoceptor selectivity; and butoxamine is 2-adrenoceptors preferring. Labetolol, in the racemic form used in medicine, acts as both a -adrenoceptor and an -adrenoceptor antagonist, though these activities reside in different isomers. Further factors determining the uses of individual agents include variations in half-life, lipid-solubility, and membrane-stabilising actions on the heart in high doses; e.g. sotalol ; . In the treatment of glaucoma, some -blockers can be used topically as eye-drops, whereas they are not used systemically e.g. carteolol ; . Clinically used antagonists have a competitive.

Were randomized to receive a long-acting preparation of metoprolol or placebo. At 24 weeks, there were no significant differences in the 6-min walk, functional class or quality of life. Metoprolol reduced activation of the angiotensin system and increased atriuretic and brain natriuretic peptide levels. Metoprolol improved LVEF and prevented the ventricular dilation noted in the placebo group. The number of patients and 6-month duration of follow-up were too limited to provide meaningful results on clinical end points. The effects of ACE inhibitor and angiotensin blocker therapy were similar to those of combination therapy, showing best improvement in LVEF. There was a trend toward improved survival with metoprolol. The overall conclusion of this pilot study was that more comprehensive neurohormonal modulation is a promising direction for future research, reflecting benefits in ventricular function and remodeling. Commentary. This complex study did not resolve the question of the relative advantages of ACE inhibitor over angiotensin blocker for treatment of heart failure. RESOLVED was a short-term study not sized to assess major clinical end points. Both the ACE inhibitor and the AII blocker had similar biochemical and physiologic effects, and the combination exerted the greatest benefit. It would seem that an adequate dose of one or the other blocker is likely to be most cost-effective.

Despite the known adverse acute hemodynamic effects of beta-blockade, there is compelling evidence that chronic beta-blockade provides long term hemodynamic, symptomatic, exercise 8 16 ; and survival benefits 13 ; in patients with congestive heart failure. Due to the negative hemodynamic effects of beta-blockers in heart failure, therapy is initiated with minute doses of beta-blockers and only gradually increased over the course of several weeks. In this study, patients treated with the shorter acting MT or the longer acting MS exhibited significant parallel long term hemodynamic improvements before the next dose of drug trough period ; following a minimum of 3 months of therapy. As was seen with MT previously 4 ; , each subsequent full dose of either metoprolol preparation, upon readministration, produced significant similar declines in CI, SVI and SWI, with an increase in SVR. A probable mechanism of this phenomenon of adverse hemodynamics with beta-blockers is a disruption of the delicate balance between the negative hemodynamic presumably as a negative inotrope ; properties of metoprolol due to adrenergic withdrawal and the beneficial effects of blocking norepinephrine thereby chronically improving left ventricular function ; . Even after three months of continuous metoprolol therapy, the negative hemodynamic effects are still measurable with the next dose peak ; , albeit with an overall net of hemodynamic and clinical benefit of chronic metoprolol therapy. The persistent adverse hemodynamic effects of MT did not differ when compared with the longer acting MS. Although we do not have drug levels to correlate with hemodynamics, the adverse hemodynamics are temporally related to drug readministration. It is important to note that the chronic adverse hemodynamic effects with subsequent dosing are not associated with any clinical deterioration. In fact, over the long term, patients demonstrate substantial clinical and hemodynamic benefits. Of perhaps even greater significance, in this study, we were able to demonstrate the safety of a more rapid initiation with a dose of 25 mg and a subsequent uptitration of MS over a two to three week period compared with the conventional initiation of the cumbersome 6.25 mg MT which requires recompounding ; and gradual uptitration of MT over a four to six week time frame. This schedule of MS would allow for a faster initiation and easier uptitration of metoprolol in clinical practice if safety is demonstrated in a larger trial. The MS dosing utilized here was more rapid than that used in.
Anxiety Clients indicated that the services offered by the SATCs, including the information provided, access to HIV PEP medications and the empathy of the staff helped to reduce their anxiety to some degree. Invaluable. Assessed quickly and respectfully, kept well-informed and continued support for management of side-effects of HIV PEP meds. All contributed to overall feeling of having received best available medical treatment, brought situation into context by allaying fear of unknown. Thank-you. Respondent 5 ; Thank you for your help. I feel much better even if the anxiety is still there and will be for the next 3 months!! Respondent 25 ; As a second time having been through this, it is much easier to try and move forward. There is a lot more peace having used the HIV PEP. Last time that wasn't even offered words can't describe how you feel. Honestly, knowing that if you may have contracted HIV and at lest have some of a chance to fight it, this gives a little piece back of what was stolen from you. It may not be much, but it sure was a start. Thank-you! Respondent 48 ; Decision-Making: Information Provided The information that clients received from the SATC staff both verbally and in writing was seen as very valuable and accessible by the clients, assisting them in addressing their fears and decisionmaking around HIV and HIV PEP kept well-informed and continued support for management of side-effects of HIV PEP meds. Respondent 5 ; The nurses . spent a lot of time with me to reassure me of the facts of HIV transmission. They were very good about leaving treatment choices with me, but at the same time offering many treatment options. Thank you for the HIV treatment study, the booklet is excellent. This program removed a very stressful component from my assault experience anxiety about HIV ; . Respondent 27 ; understood clearly and all questions were answered. Respondent 72 ; Quality of Care: SATC Staff Client satisfaction with the quality of care they received was very high. They found the SATC staff to be knowledgeable, respectful and supportive They made me feel more comfortable and relaxed. Respondent 61 ; I was given the greatest care and was treated with respect in a situation that no one wants to deal with . Respondent 73 ; Great facility and nurses. I didn't feel pressured to feel anything I was not feeling ; no pressure to talk, cry etc. Very knowledgeable and made me feel extremely comfortable. Thanks for everything! Respondent 17 ; They are wonderful, trained employees who deal very well with the individual in such a stressful situation. They are very informed and provide you with the necessary information. I never thought I would need a S.A.T.C., but I so thankful they did exist when I needed one. Thank you. Respondent 56.
INITIAL APPLICATION Applications from any medical practitioner. Approvals valid without further renewal unless notified. Prerequisites tick box where appropriate.